Leerink Partnrs Has Strong Forecast for ALNY FY2026 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Leerink Partnrs lifted their FY2026 EPS estimates for shares of Alnylam Pharmaceuticals in a report released on Tuesday, October 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the biopharmaceutical company will earn $6.73 per share for the year, up from their previous forecast of $6.62. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ FY2027 earnings at $11.70 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other research analysts have also commented on ALNY. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Evercore ISI lifted their price objective on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Jefferies Financial Group increased their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a “buy” rating in a research note on Monday, July 7th. UBS Group upped their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, BMO Capital Markets boosted their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Twenty-four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $457.08.

Alnylam Pharmaceuticals Trading Up 0.2%

Shares of ALNY opened at $470.27 on Wednesday. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $485.28. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company’s fifty day moving average is $454.12 and its 200 day moving average is $349.19. The stock has a market capitalization of $61.64 billion, a PE ratio of -190.39 and a beta of 0.36.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $662,837,000. Holocene Advisors LP purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $194,616,000. Orbis Allan Gray Ltd raised its position in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $69,292,000. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 8,924 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the transaction, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares of the company’s stock, valued at approximately $397,724.38. This trade represents a 97.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock valued at $44,160,261 over the last 90 days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.